FindTrial
Sign In

Expanded Access to Cefiderocol for the Intravenous Treatment of Severe Gram Negative Bacterial Infections

Expanded Access to Cefiderocol for the Intravenous Treatment of Severe Gram Negative Bacterial Infections

Status
APPROVED_FOR_MARKETING
Phases
Unknown
Study type
Expanded Access
Source
ClinicalTrials.gov
Registry ID
NCT03780140
Enrollment
Unknown
Registered
2018-12-19
Start date
Unknown
Completion date
Unknown
Last updated
2020-02-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Bacterial Infections

Keywords

S-649266, cefiderocol, Gram-negative

Brief summary

Expanded access may be provided for cefiderocol for qualified patients who have limited treatment options and are not eligible for a clinical trial.

Interventions

DRUGCefiderocol

Cefiderocol for intravenous infusion

Sponsors

Shionogi
Lead SponsorINDUSTRY

Eligibility

Sex/Gender
ALL

Inclusion criteria

Hospitalized patients with serious Gram-negative bacterial infections and who have limited treatment options and are not eligible for a clinical trial.

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026